These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 16239770)
1. Reversible Pisa syndrome in Parkinson's disease during treatment with pergolide: a case report. Cannas A; Solla P; Floris G; Borghero G; Tacconi P; Spissu A Clin Neuropharmacol; 2005; 28(5):252. PubMed ID: 16239770 [No Abstract] [Full Text] [Related]
2. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide. Jiménez-Jiménez FJ; López-Alvarez J; Sánchez-Chapado M; Montero E; Miquel J; Sierra A; Gutiérrez F Clin Neuropharmacol; 1995 Jun; 18(3):277-9. PubMed ID: 8635187 [TBL] [Abstract][Full Text] [Related]
3. Pergolide in Parkinson's disease: time for a change? Grosset KA; Grosset DG Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636 [No Abstract] [Full Text] [Related]
4. Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease. Bilici A; Karadag B; Doventas A; Erdincler DS; Cetinkaya S; Ogut G; Tezcan V; Beger T Neth J Med; 2004 Nov; 62(10):389-92. PubMed ID: 15683095 [TBL] [Abstract][Full Text] [Related]
5. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis. Lund BC; Neiman RF; Perry PJ Pharmacotherapy; 1999 Dec; 19(12):1437-8. PubMed ID: 10600093 [TBL] [Abstract][Full Text] [Related]
6. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Van Camp G; Flamez A; Cosyns B; Goldstein J; Perdaens C; Schoors D Neurology; 2003 Sep; 61(6):859-61. PubMed ID: 14504342 [TBL] [Abstract][Full Text] [Related]
7. [Pergolide: a useful agonist for the treatment of Parkinson disease]. Bonnet AM; Houeto JL Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908 [TBL] [Abstract][Full Text] [Related]
8. Refractory generalized edema: an infrequent complication of long-term pergolide treatment for Parkinson disease. Bianchi M; Castiglioni MG Clin Neuropharmacol; 2005; 28(5):245-6. PubMed ID: 16239767 [TBL] [Abstract][Full Text] [Related]
9. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent. Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828 [No Abstract] [Full Text] [Related]
10. Antisaccadic effects of a dopamine agonist as add-on therapy in advanced Parkinson's patients. Crevits L; Versijpt J; Hanse M; De Ridder K Neuropsychobiology; 2000; 42(4):202-6. PubMed ID: 11096336 [TBL] [Abstract][Full Text] [Related]
12. The long-lasting improvement of sexual dysfunction in patients with advanced, fluctuating Parkinson's disease induced by pergolide: evidence from the results of an open, prospective, one-year trial. Pohanka M; Kanovský P; Bares M; Pulkrábek J; Rektor I Parkinsonism Relat Disord; 2005 Dec; 11(8):509-12. PubMed ID: 15994112 [TBL] [Abstract][Full Text] [Related]
13. Medical hazards of the internet: gambling in Parkinson's disease. Larner AJ Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457 [No Abstract] [Full Text] [Related]
14. [Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use]. van Strater AC; Bax JJ; van Hilten JJ; Jukema JW Ned Tijdschr Geneeskd; 2005 Apr; 149(16):891-4. PubMed ID: 15868996 [TBL] [Abstract][Full Text] [Related]
20. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease. Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]